Jordi Remon, Chair Lung Cancer Group at EORTC, shared on X:
“Final PECATI trial supports Pembro and Lenvatinib in pretreated met B3 thymoma and thymic Ca.
- mINV-PFS: 22 mo | OS: 40 mo
- Can IO, ADCs and bispecifics move to 1st line?
More academic and pharma collaboration is needed in rare thoracic malignancies!”
PECATI Phase 2 Trial main findings
- The final PECATI Phase 2 analysis found that lenvatinib plus pembrolizumab achieved a median progression-free survival (PFS) of 22.1 months in 43 patients with previously treated advanced B3 thymoma or thymic carcinoma.
- Median overall survival reached 40.2 months, with a 36-month survival rate of 53.0%. The confirmed overall response rate was 25.6%, including one complete response, while the disease control rate reached 93%.
- Patients without liver metastases experienced significantly longer median PFS than those with liver involvement (24.9 versus 10.9 months). This suggests liver metastases may identify a subgroup with less favorable outcomes.
- Treatment-related adverse events were common, with grade 3 or higher events reported in 44.2% of patients. Twelve patients discontinued at least one treatment due to toxicity, emphasizing the importance of close monitoring and proactive adverse-event management.
Title: Final Analysis From PECATI Phase 2 Trial: Lenvatinib in Combination With Pembrolizumab in Pretreated Advanced B3 Thymoma and Thymic Carcinoma
Authors: Jordi Remon, Paolo Bironzo, Nicolas Girard, Laurence Bigay-Game, Oscar Juan-Vidal, Javier de Castro, Noemí Reguart, Laurent Greillier, Sophie Cousin, Eric Dansin, Margarita Majem, Reyes Bernabé, Joaquin Mosquera-Martinez, Marta Díaz, Alba Meya, Daniel Alcalá-López, Alicia García-Sanz, Luisella Righi, Silvia Novello, Benjamin Besse
Read the full article:
You may also be interested in:
Katy Beckermann: Adding a Third Drug to Pembrolizumab Plus Lenvatinib in First-Line Clear Cell RCC
Jordi Remon: Celebrating the Autumn EORTC Lung Cancer Group Meeting
Nagla Abdel Karim Highlights Rising Global Incidence of Thymic Cancer